Hepatitis C, Chronic
Conditions
Brief summary
A Phase 2, Multicenter, Randomized, Open-label, Dose-ranging Study to Evaluate the Efficacy and Safety of TG-2349 in Combination with Peg-interferon and Ribavirin in Treatment Naïve East Asian Subjects with Chronic Hepatitis C Virus Genotype 1b Infection.
Detailed description
It is a multicenter, randomized, open-label study to evaluate the safety, tolerability, and antiviral efficacy of two different doses of TG-2349 combined with Peg-interferon (IFN) and Ribavirin (RBV) in HCV-GT1b treatment naïve East Asian subjects. The treatment duration of TG-2349+IFN+RBV is 12 weeks, with or without an additional 12-week treatment of IFN+RBV, depending on HCV RNA level at On-Treatment Week 4. Approximately 24 subjects will be randomized (1:1) to one of the following 2 treatment groups: * Group I (n=12): 200 mg TG-2349 (2 capsules) + IFN + RBV * Group II (n=12): 400 mg TG-2349 (4 capsules) + IFN + RBV Randomization will be stratified by IL28B genotype CC or non-CC. Subjects with HCV RNA \< LLOQ (lower limit of quantification), TD (target detected) or TND (target not detected) at Week 4 will receive 12 weeks of TG-2349+IFN+RBV treatment. Subjects with HCV RNA ≥ LLOQ but \< 100 IU/mL at Week 4 will receive 12 weeks of TG-2349+IFN+RBV treatment followed by an additional 12 weeks of IFN+RBV treatment. However, subjects with HCV RNA ≥ 100 IU/mL at Week 4 will discontinue the study treatment and complete the Early-Termination (ET) visit. The study will be terminated if 3 or more of the first 12 subjects enrolled across both Groups I and II, or ≥ 25% of subjects thereafter, fail to respond to treatment (i.e., confirmed on-treatment virologic failure or post-treatment relapse). Patients, except those who have achieved SVR12, will be offered the standard of care with Peg-interferon and Ribavirin for duration of 24, 48, or 72 weeks based on Taiwan's regulatory guideline and principal investigator's judgment.
Interventions
DRUGTG-2349
TG-2349 (Furaprevir) is available as a Swedish orange capsule (size 0) for oral administration. Each capsule contains an equivalent of 100 mg of TG-2349 spray dried solid (SDD) and the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, and colloidal silicon oxide.
DRUGRibavirin
RBV (Ribavirin or COPEGUS®) is available as a light pink to pink colored, flat, oval-shaped, film-coated tablet for oral administration. Each tablet contains 200 mg of ribavirin and the following inactive ingredients: pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, cornstarch, and magnesium stearate. The coating of the tablet contains Chromatone-P® or Opadry® Pink (made by using hydroxypropyl methyl cellulose, talc, titanium dioxide, synthetic yellow iron oxide, and synthetic red iron oxide), ethyl cellulose (ECD-30), and triacetin.
IFN (Interferon, Peg-interferon alpha-2a or PEGASYS®) is available as a sterile, preservative-free, colorless to light yellow injectable solution administered subcutaneously. Each prefilled syringe of 180 μg/0.5 mL IFN (expressed as the amount of interferon alfa-2a) also contains acetic acid (0.0231 mg), benzyl alcohol (5 mg), polysorbate 80 (0.025 mg), sodium acetate trihydrate (1.3085 mg), and sodium chloride (4 mg) at pH 6 ± 0.5.
Sponsors
TaiGen Biotechnology Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Willing and able to provide written informed consent. 2. East Asian subjects, male or female, and age between 18 (or legal adult age) and 70 years, inclusive, at Baseline/Day 1. 3. Body mass index (BMI) in the range of 18.0 to 35.0 kg/m2 (inclusive) and body weight ≥ 40 kg. 4. Presence of chronic hepatitis C (CHC) as documented below: (1) A positive anti-HCV antibody test or positive HCV RNA or positive HCV genotyping test at least 6 months prior to the Baseline/Day 1 visit or (2) A liver biopsy or FibroTest performed prior to the Baseline/Day 1 visit with evidence of chronic HCV infection, such as the presence of fibrosis and/or inflammation. 5\. Positive for anti-HCV antibody at Screening. 6. Presence of an HCV RNA level ≥ 1 x 10000 IU/mL at Screening as determined by the Central Laboratory. 7\. Presence of genotype 1b HCV-infection at Screening as determined by the Central Laboratory. Any non-definitive results will exclude the subject from study participation. 8\. HCV treatment naïve defined as no prior therapy with any interferon (IFN), ribavirin (RBV), or other approved or investigational HCV-specific agent. 9\. Absence of cirrhosis Cirrhosis as defined as any one of the following: 1. Liver biopsy showing cirrhosis (e.g., Metavir score = 4 or Ishak score ≥ 5). 2. FibroScan showing cirrhosis or results \> 12.5 kPa. 3. FibroTest fibrosis score of \> 0.58 and APRI (AST: platelet ratio index) of \> 2 during Screening. If no definitive diagnosis of cirrhosis by the above criteria, a liver biopsy is required; liver biopsy results will supersede non-invasive testing results and be considered definitive. 10\. Screening ECG without clinically significant abnormalities. 11. Subjects must have the following laboratory parameters at Screening: 1. ALT ≤ 10 × the upper limit of normal (ULN) 2. AST ≤ 10 × ULN 3. Total bilirubin ≤ 1.5 × ULN except history of Gilbert's syndrome. If Gilbert's syndrome is the proposed etiology, the total bilirubin must ≤ 2 × ULN. 4. Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3 5. Platelet count ≥ 90,000 cells/mm3 6. HbA1c ≤ 8.5% 7. Thyroid stimulating hormone (TSH) and free T4 ≤ ULN 8. Creatinine clearance (CLcr) ≥ 60 mL /min, as calculated by the Cockcroft-Gault equation 9. Serum creatinine ≤ 1.5 × ULN 10. Hemoglobin ≥ 11 g/dL for female subjects; ≥ 12 g/dL for male subjects 11. Albumin ≥ 3.5 g/dL 12. INR (International Normalized Ratio for Prothrombin Time) ≤ 1.5 x ULN unless subject is stable on an anticoagulant regimen affecting INR 13. Anti-nuclear antibodies (ANA) ≤ 1:320. 12. Subject must be of generally good health, with the exception of chronic HCV infection, as determined by Investigator. 13\. Subject must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments, including all required Post-Treatment visits. 14\. A female subject is eligible to enter the study if it is confirmed that she is: (1) Not pregnant or nursing. (2) Of non-childbearing potential (i.e., women who have had a hysterectomy, have both ovaries removed or medically documented ovarian failure, or are postmenopausal - women \> 50 years of age with cessation (for ≥12 months) of previously occurring menses), or (3) Of childbearing potential (i.e., women who have not had a hysterectomy, have not had both ovaries removed, and have not had medically documented ovarian failure). Women ≤ 50 years of age with amenorrhea will be considered to be of childbearing potential. These women must have a negative serum pregnancy test at Screening and a negative urine pregnancy test at the Baseline/Day 1 visit prior to randomization. They must also agree to one of the following from Screening until 6 months after the last dose of study drug(s): \- Complete abstinence from intercourse. Periodic abstinence from intercourse (e.g., calendar, ovulation, symptothermal, post-ovulation methods) is not permitted. Or - Consistent and correct use of 1 of the following methods of birth control listed below, in addition to a male partner who correctly uses a condom, from Screening until 6 months after the last dose of study drug(s): 1. intrauterine device (IUD) with a failure rate of \< 1% per year 2. female barrier method: cervical cap or diaphragm with spermicidal agent 3. tubal sterilization 4. vasectomy in male partner 5. hormone-containing contraceptive: i. implants of levonorgestrel ii. injectable progesterone iii. oral contraceptives (either combined or progesterone only) iv. contraceptive vaginal ring v. transdermal contraceptive patch. 15. Male subjects must agree to consistently and correctly use a condom, while their female partner agrees to use 1 of the methods of birth control listed above, from Screening until 6 months after the last dose of study drug(s). 16\. Male subjects must agree to refrain from sperm donation from Screening until at least 6 months after the last dose of study drug(s).
Exclusion criteria
1. Presence of cirrhosis. 2. Positive serological test for IgM anti-HAV (hepatitis A virus) antibody or HBsAg at Screening. 3. Positive ELISA test for HIV-1 or HIV-2 at Screening. 4. Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson disease, alfa-1 antitrypsin deficiency, cholangitis). 5. Donation or loss of more than 400 mL blood within 2 months prior to Baseline/Day 1. 6. Clinically-relevant drug abuse within 12 months of Screening. A positive drug screen will exclude subjects unless it can be explained by a prescribed medication; the diagnosis and prescription must be approved by Investigator. 7. Alcohol misuse as defined by an AUDIT score of ≥ 8. 8. Contraindications to RBV or IFN therapy, including hemoglobinopathies (e.g., thalassemia major or sickle-cell anemia), autoimmune thyroiditis or other autoimmune disorders including autoimmune hepatitis. 9. Pregnant or nursing female or male with pregnant female partner. 10. Use of any prohibited medications within 30 days of the Baseline/Day 1 visit: (1) Hematologic stimulating agents (e.g., erythropoiesis-stimulating agents \[ESAs\], granulocyte colony stimulating factor \[G-CSF\], and thrombopoietin \[TPO\] mimetics) (2) Chronic use of systemic immunosuppressants including, but not limited to, corticosteroids (prednisone equivalent of \> 10 mg/day for \> 2 weeks), azathioprine, or monoclonal antibodies (eg, infliximab) (3) Investigational agents or devices for any indication (4) Drugs disallowed per prescribing information of RBV or IFN (5) Any prohibited medications listed in Table 6-2. 11. Known hypersensitivity to RBV, IFN, TG-2349, sulfa drugs, or formulation excipients. 12\. Current or prior history of any of the following: 1. Clinically-significant illness (other than HCV) or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol; subjects currently under evaluation for a potentially clinically-significant illness (other than HCV) are also excluded. 2. Gastrointestinal disorder or post operative condition that could interfere with the absorption of the study drugs. 3. Difficulty with blood collection and/or poor venous access for the purposes of phlebotomy. 4. Clinical hepatic decompensation (i.e., ascites, encephalopathy or variceal hemorrhage). 5. Central nervous system (CNS) trauma, seizure disorder, stroke or transient ischemic attack. 6. Solid organ transplantation. 7. Significant cardiac disease (including but not limited to the myocardial infarction based on ECG and/or clinical history). 8. Significant pulmonary disease or porphyria. 9. Clinically significant retinal disease 10. Psychiatric hospitalization, suicide attempt, and/or a period of disability as a result of their psychiatric illness within the last 5 years. Subjects with psychiatric illness (without the prior mentioned conditions) that is well-controlled on a stable treatment regimen for at least 12 months prior to Baseline/Day 1 or has not required medication in the last 12 months may be included. 11. Malignancy within 5 years prior to Screening, with the exception of specific cancers that are entirely cured by surgical resection (basal cell skin cancer, etc). Subjects under evaluation for possible malignancy are not eligible. 12. Significant drug allergy (such as anaphylaxis or hepatotoxicity).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Subjects Achieving Sustained Viral Response at 12 Weeks After the End of Treatment. | 12 weeks after the end of treatment (SVR12), after 12-week treatments | Proportion of subjects with HCV RNA\< LLOQ (lower limit of quantification), TD (target detected) or TND (target not detected) at 12 weeks after the end of treatment (SVR12) in the Full Analysis Set (FAS) population, which include subjects with genotype 1b HCV infection who were enrolled and received at least one dose of study drugs. |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of Subjects Achieving HCV RNA < Lower Limit of Quantification, Target Detected or Target Not Detected (< LLOQ, TD or TND) | The whole treatment period, 12 weeks |
| Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Treatment period (12 to 24 weeks) and after the end of treatment (12 to 24 weeks) |
| Mean Absolute Values in HCV RNA (log10 IU/mL) | Treatment period (12 to 24 weeks) and after the end of treatment (12 to 24 weeks) |
| Proportion of Subjects Achieving Sustained Viral Response at 4, 8, and 24 Weeks After the End of Treatment (SVR4, SVR8, and SVR24) | 4, 8, 24 weeks after the end of treatment (SVR4, 8, 24), after 12-week treatments |
| Proportion of Subjects With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal Limit of ALT at Final Treatment Visit. | From baseline (day 1) to the final treatment visit (week 12 or week 24) |
| Change From Baseline in HCV RNA (log10 IU/mL) | Treatment period (12 to 24 weeks) and after the end of treatment (12 to 24 weeks) |
| Proportion of Subjects Experiencing Virologic Failure During Treatment and Viral Relapse After the End of Treatment. | Treatment period (12 to 24 weeks) and after the end of treatment (12 to 24 weeks) |
Countries
Taiwan
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| 200 mg TG-2349 200 mg TG-2349 (2 capsules) + Interferon or Peg-interferon + Ribavirin | 13 |
| 400 mg TG-2349 400 mg TG-2349 (4 capsules) + Interferon or Peg-interferon + Ribavirin | 12 |
| Total | 25 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Lost to Follow-up | 1 | 0 |
Baseline characteristics
| Characteristic | 200 mg TG-2349 | Total | 400 mg TG-2349 |
|---|---|---|---|
| Age, Continuous | 50.8 years STANDARD_DEVIATION 10.76 | 52.3 years STANDARD_DEVIATION 11.21 | 54.0 years STANDARD_DEVIATION 11.91 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 13 Participants | 25 Participants | 12 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Female | 8 Participants | 13 Participants | 5 Participants |
| Sex: Female, Male Male | 5 Participants | 12 Participants | 7 Participants |
| Weight | 62.8 kilogram STANDARD_DEVIATION 13.69 | 63.4 kilogram STANDARD_DEVIATION 11.49 | 64.0 kilogram STANDARD_DEVIATION 9.11 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 13 | 0 / 12 |
| other Total, other adverse events | 13 / 13 | 12 / 12 |
| serious Total, serious adverse events | 2 / 13 | 2 / 12 |
Outcome results
Primary
Proportion of Subjects Achieving Sustained Viral Response at 12 Weeks After the End of Treatment.
Proportion of subjects with HCV RNA\< LLOQ (lower limit of quantification), TD (target detected) or TND (target not detected) at 12 weeks after the end of treatment (SVR12) in the Full Analysis Set (FAS) population, which include subjects with genotype 1b HCV infection who were enrolled and received at least one dose of study drugs.
Time frame: 12 weeks after the end of treatment (SVR12), after 12-week treatments
Population: Full Analysis Set (FAS) population includes subjects with genotype 1b HCV infection who were enrolled and received at least one dose of study drugs.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| 200 mg TG-2349 | Proportion of Subjects Achieving Sustained Viral Response at 12 Weeks After the End of Treatment. | 11 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving Sustained Viral Response at 12 Weeks After the End of Treatment. | 10 Participants |
Secondary
Change From Baseline in HCV RNA (log10 IU/mL)
Time frame: Treatment period (12 to 24 weeks) and after the end of treatment (12 to 24 weeks)
Population: Full Analysis Set (FAS) population includes subjects with genotype 1b HCV infection who were enrolled and received at least one dose of study drugs.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| 200 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Week 2 | -4.8 log10 IU/mL | Standard Deviation 0.91 |
| 200 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Week 8 | -5.8 log10 IU/mL | Standard Deviation 0.9 |
| 200 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Day 4 | -3.8 log10 IU/mL | Standard Deviation 0.51 |
| 200 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Week 10 | -5.6 log10 IU/mL | Standard Deviation 0.86 |
| 200 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Week 3 | -5.0 log10 IU/mL | Standard Deviation 1.03 |
| 200 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Week 12 | -5.8 log10 IU/mL | Standard Deviation 0.9 |
| 200 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Post-Treatment Week 4 | -5.8 log10 IU/mL | Standard Deviation 0.86 |
| 200 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Day 10 | -4.6 log10 IU/mL | Standard Deviation 0.75 |
| 200 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Post-Treatment Week 8 | -5.6 log10 IU/mL | Standard Deviation 0.88 |
| 200 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Week 4 | -5.2 log10 IU/mL | Standard Deviation 0.79 |
| 200 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Post-Treatment Week 12 | -5.2 log10 IU/mL | Standard Deviation 1.81 |
| 200 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Week 1 | -4.4 log10 IU/mL | Standard Deviation 0.5 |
| 200 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Post-Treatment Week 24 | -5.6 log10 IU/mL | Standard Deviation 0.83 |
| 200 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Week 6 | -5.4 log10 IU/mL | Standard Deviation 0.86 |
| 400 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Post-Treatment Week 24 | -5.8 log10 IU/mL | Standard Deviation 0.7 |
| 400 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Day 4 | -3.9 log10 IU/mL | Standard Deviation 0.55 |
| 400 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Week 1 | -4.5 log10 IU/mL | Standard Deviation 0.56 |
| 400 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Day 10 | -4.8 log10 IU/mL | Standard Deviation 0.78 |
| 400 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Week 2 | -4.9 log10 IU/mL | Standard Deviation 1.01 |
| 400 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Week 3 | -5.5 log10 IU/mL | Standard Deviation 0.96 |
| 400 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Week 4 | -5.5 log10 IU/mL | Standard Deviation 0.73 |
| 400 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Week 6 | -5.7 log10 IU/mL | Standard Deviation 0.65 |
| 400 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Week 8 | -5.7 log10 IU/mL | Standard Deviation 0.7 |
| 400 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Week 10 | -5.8 log10 IU/mL | Standard Deviation 0.67 |
| 400 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Post-Treatment Week 4 | -5.1 log10 IU/mL | Standard Deviation 1.72 |
| 400 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Post-Treatment Week 8 | -5.0 log10 IU/mL | Standard Deviation 2.05 |
| 400 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Post-Treatment Week 12 | -4.8 log10 IU/mL | Standard Deviation 2.1 |
| 400 mg TG-2349 | Change From Baseline in HCV RNA (log10 IU/mL) | Week 12 | -5.7 log10 IU/mL | Standard Deviation 0.68 |
Secondary
Mean Absolute Values in HCV RNA (log10 IU/mL)
Time frame: Treatment period (12 to 24 weeks) and after the end of treatment (12 to 24 weeks)
Population: Full Analysis Set (FAS) population includes subjects with genotype 1b HCV infection who were enrolled and received at least one dose of study drugs.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| 200 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Baseline | 5.8 log10 IU/mL | Standard Deviation 0.83 |
| 200 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Week 8 | 0.0 log10 IU/mL | Standard Deviation 0 |
| 200 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Week 1 | 1.4 log10 IU/mL | Standard Deviation 0.52 |
| 200 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Week 10 | 0.2 log10 IU/mL | Standard Deviation 0.42 |
| 200 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Week 3 | 0.7 log10 IU/mL | Standard Deviation 0.51 |
| 200 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Week 12 | 0.0 log10 IU/mL | Standard Deviation 0 |
| 200 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Day 4 | 1.9 log10 IU/mL | Standard Deviation 0.4 |
| 200 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Post-Treatment Week 4 | 0.0 log10 IU/mL | Standard Deviation 0 |
| 200 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Week 4 | 0.5 log10 IU/mL | Standard Deviation 0.54 |
| 200 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Post-Treatment Week 8 | 0.2 log10 IU/mL | Standard Deviation 0.57 |
| 200 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Day 10 | 1.2 log10 IU/mL | Standard Deviation 0.19 |
| 200 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Post-Treatment Week 12 | 0.5 log10 IU/mL | Standard Deviation 1.86 |
| 200 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Week 6 | 0.4 log10 IU/mL | Standard Deviation 0.53 |
| 200 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Post-Treatment Week 24 | 0.1 log10 IU/mL | Standard Deviation 0.31 |
| 200 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Week 2 | 1.0 log10 IU/mL | Standard Deviation 0.48 |
| 400 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Post-Treatment Week 24 | 0.0 log10 IU/mL | Standard Deviation 0 |
| 400 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Baseline | 5.9 log10 IU/mL | Standard Deviation 0.66 |
| 400 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Day 4 | 2.0 log10 IU/mL | Standard Deviation 0.74 |
| 400 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Week 1 | 1.4 log10 IU/mL | Standard Deviation 0.54 |
| 400 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Day 10 | 1.1 log10 IU/mL | Standard Deviation 0.83 |
| 400 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Week 2 | 1.0 log10 IU/mL | Standard Deviation 0.72 |
| 400 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Week 3 | 0.4 log10 IU/mL | Standard Deviation 0.78 |
| 400 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Week 4 | 0.4 log10 IU/mL | Standard Deviation 0.71 |
| 400 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Week 6 | 0.1 log10 IU/mL | Standard Deviation 0.31 |
| 400 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Week 8 | 0.1 log10 IU/mL | Standard Deviation 0.31 |
| 400 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Week 10 | 0.0 log10 IU/mL | Standard Deviation 0 |
| 400 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Week 12 | 0.1 log10 IU/mL | Standard Deviation 0.31 |
| 400 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Post-Treatment Week 4 | 0.8 log10 IU/mL | Standard Deviation 1.79 |
| 400 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Post-Treatment Week 8 | 0.9 log10 IU/mL | Standard Deviation 2.13 |
| 400 mg TG-2349 | Mean Absolute Values in HCV RNA (log10 IU/mL) | Post-Treatment Week 12 | 1.0 log10 IU/mL | Standard Deviation 2.22 |
Secondary
Proportion of Subjects Achieving HCV RNA < LLOQ, TND
Time frame: Treatment period (12 to 24 weeks) and after the end of treatment (12 to 24 weeks)
Population: Full Analysis Set (FAS) population includes subjects with genotype 1b HCV infection who were enrolled and received at least one dose of study drugs. Missing data were excluded in the dominator of on-treatment visits, while imputation was performed at post-treatment visits and the dominator for post-treatment visits was the total population.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 200 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Week 2 | 2 Participants |
| 200 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Week 8 | 11 Participants |
| 200 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Day 4 | 0 Participants |
| 200 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Week 10 | 9 Participants |
| 200 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Week 3 | 4 Participants |
| 200 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Week 12 | 11 Participants |
| 200 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Day 10 | 0 Participants |
| 200 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Post-Treatment Week 4 | 12 Participants |
| 200 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Week 4 | 6 Participants |
| 200 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Post-Treatment Week 8 | 11 Participants |
| 200 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Week 1 | 1 Participants |
| 200 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Post-Treatment Week 12 | 11 Participants |
| 200 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Week 6 | 7 Participants |
| 200 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Post-Treatment Week 24 | 10 Participants |
| 200 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Baseline | 0 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Post-Treatment Week 24 | 10 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Baseline | 0 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Day 4 | 0 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Week 1 | 1 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Day 10 | 3 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Week 2 | 4 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Week 3 | 9 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Week 4 | 9 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Week 6 | 10 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Week 8 | 10 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Week 10 | 11 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Week 12 | 10 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Post-Treatment Week 4 | 10 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Post-Treatment Week 8 | 10 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < LLOQ, TND | Post-Treatment Week 12 | 9 Participants |
Secondary
Proportion of Subjects Achieving HCV RNA < Lower Limit of Quantification, Target Detected or Target Not Detected (< LLOQ, TD or TND)
Time frame: The whole treatment period, 12 weeks
Population: Full Analysis Set (FAS) population includes subjects with genotype 1b HCV infection who were enrolled and received at least one dose of study drugs. Missing data were excluded in the dominator of on-treatment visits.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 200 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < Lower Limit of Quantification, Target Detected or Target Not Detected (< LLOQ, TD or TND) | Day 10 | 6 Participants |
| 200 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < Lower Limit of Quantification, Target Detected or Target Not Detected (< LLOQ, TD or TND) | Week 4 | 12 Participants |
| 200 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < Lower Limit of Quantification, Target Detected or Target Not Detected (< LLOQ, TD or TND) | Week 1 | 3 Participants |
| 200 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < Lower Limit of Quantification, Target Detected or Target Not Detected (< LLOQ, TD or TND) | Week 6 | 11 Participants |
| 200 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < Lower Limit of Quantification, Target Detected or Target Not Detected (< LLOQ, TD or TND) | Week 2 | 9 Participants |
| 200 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < Lower Limit of Quantification, Target Detected or Target Not Detected (< LLOQ, TD or TND) | Week 8 | 11 Participants |
| 200 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < Lower Limit of Quantification, Target Detected or Target Not Detected (< LLOQ, TD or TND) | Day 4 | 1 Participants |
| 200 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < Lower Limit of Quantification, Target Detected or Target Not Detected (< LLOQ, TD or TND) | Week 10 | 11 Participants |
| 200 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < Lower Limit of Quantification, Target Detected or Target Not Detected (< LLOQ, TD or TND) | Week 3 | 11 Participants |
| 200 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < Lower Limit of Quantification, Target Detected or Target Not Detected (< LLOQ, TD or TND) | Week 12 | 11 Participants |
| 200 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < Lower Limit of Quantification, Target Detected or Target Not Detected (< LLOQ, TD or TND) | Baseline | 0 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < Lower Limit of Quantification, Target Detected or Target Not Detected (< LLOQ, TD or TND) | Week 12 | 11 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < Lower Limit of Quantification, Target Detected or Target Not Detected (< LLOQ, TD or TND) | Baseline | 0 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < Lower Limit of Quantification, Target Detected or Target Not Detected (< LLOQ, TD or TND) | Day 4 | 0 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < Lower Limit of Quantification, Target Detected or Target Not Detected (< LLOQ, TD or TND) | Week 1 | 4 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < Lower Limit of Quantification, Target Detected or Target Not Detected (< LLOQ, TD or TND) | Day 10 | 8 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < Lower Limit of Quantification, Target Detected or Target Not Detected (< LLOQ, TD or TND) | Week 2 | 10 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < Lower Limit of Quantification, Target Detected or Target Not Detected (< LLOQ, TD or TND) | Week 3 | 10 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < Lower Limit of Quantification, Target Detected or Target Not Detected (< LLOQ, TD or TND) | Week 4 | 11 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < Lower Limit of Quantification, Target Detected or Target Not Detected (< LLOQ, TD or TND) | Week 6 | 11 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < Lower Limit of Quantification, Target Detected or Target Not Detected (< LLOQ, TD or TND) | Week 8 | 11 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving HCV RNA < Lower Limit of Quantification, Target Detected or Target Not Detected (< LLOQ, TD or TND) | Week 10 | 11 Participants |
Secondary
Proportion of Subjects Achieving Sustained Viral Response at 4, 8, and 24 Weeks After the End of Treatment (SVR4, SVR8, and SVR24)
Time frame: 4, 8, 24 weeks after the end of treatment (SVR4, 8, 24), after 12-week treatments
Population: Full Analysis Set (FAS) population includes subjects with genotype 1b HCV infection who were enrolled and received at least one dose of study drugs.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 200 mg TG-2349 | Proportion of Subjects Achieving Sustained Viral Response at 4, 8, and 24 Weeks After the End of Treatment (SVR4, SVR8, and SVR24) | SVR4 | 12 Participants |
| 200 mg TG-2349 | Proportion of Subjects Achieving Sustained Viral Response at 4, 8, and 24 Weeks After the End of Treatment (SVR4, SVR8, and SVR24) | SVR8 | 11 Participants |
| 200 mg TG-2349 | Proportion of Subjects Achieving Sustained Viral Response at 4, 8, and 24 Weeks After the End of Treatment (SVR4, SVR8, and SVR24) | SVR24 | 11 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving Sustained Viral Response at 4, 8, and 24 Weeks After the End of Treatment (SVR4, SVR8, and SVR24) | SVR4 | 10 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving Sustained Viral Response at 4, 8, and 24 Weeks After the End of Treatment (SVR4, SVR8, and SVR24) | SVR8 | 10 Participants |
| 400 mg TG-2349 | Proportion of Subjects Achieving Sustained Viral Response at 4, 8, and 24 Weeks After the End of Treatment (SVR4, SVR8, and SVR24) | SVR24 | 10 Participants |
Secondary
Proportion of Subjects Experiencing Virologic Failure During Treatment and Viral Relapse After the End of Treatment.
Time frame: Treatment period (12 to 24 weeks) and after the end of treatment (12 to 24 weeks)
Population: Full Analysis Set (FAS) population includes subjects with genotype 1b HCV infection who were enrolled and received at least one dose of study drugs.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 200 mg TG-2349 | Proportion of Subjects Experiencing Virologic Failure During Treatment and Viral Relapse After the End of Treatment. | Virologic failure | 1 Participants |
| 200 mg TG-2349 | Proportion of Subjects Experiencing Virologic Failure During Treatment and Viral Relapse After the End of Treatment. | On-Treatment failure | 0 Participants |
| 200 mg TG-2349 | Proportion of Subjects Experiencing Virologic Failure During Treatment and Viral Relapse After the End of Treatment. | Post-Treatment relapse | 1 Participants |
| 400 mg TG-2349 | Proportion of Subjects Experiencing Virologic Failure During Treatment and Viral Relapse After the End of Treatment. | Virologic failure | 2 Participants |
| 400 mg TG-2349 | Proportion of Subjects Experiencing Virologic Failure During Treatment and Viral Relapse After the End of Treatment. | On-Treatment failure | 1 Participants |
| 400 mg TG-2349 | Proportion of Subjects Experiencing Virologic Failure During Treatment and Viral Relapse After the End of Treatment. | Post-Treatment relapse | 1 Participants |
Secondary
Proportion of Subjects With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal Limit of ALT at Final Treatment Visit.
Time frame: From baseline (day 1) to the final treatment visit (week 12 or week 24)
Population: Full Analysis Set (FAS) population includes subjects with genotype 1b HCV infection who were enrolled and received at least one dose of study drugs.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 200 mg TG-2349 | Proportion of Subjects With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal Limit of ALT at Final Treatment Visit. | ALT > ULN at baseline | 7 Participants |
| 200 mg TG-2349 | Proportion of Subjects With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal Limit of ALT at Final Treatment Visit. | ALT normalization | 2 Participants |
| 400 mg TG-2349 | Proportion of Subjects With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal Limit of ALT at Final Treatment Visit. | ALT > ULN at baseline | 7 Participants |
| 400 mg TG-2349 | Proportion of Subjects With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal Limit of ALT at Final Treatment Visit. | ALT normalization | 5 Participants |